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a panel of nonviral cancer antigens in HPV‐positive and HPV‐negative HNSCC patients. A fluorescent
microbead multiplex serology to 29 cancer antigens (16 cancer‐testis antigens, 5 cancer‐retina antigens and
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(153 HPV‐positive and 209 HPV‐negative). AR to any of the cancer antigens were found in 272/382
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‐A4, NY‐ESO‐1, SpanX‐a1 and p53. AR to MAGE‐A3, MAGE‐A9 and p53 were found at significantly
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remarkably different AR clusters by HPV status. To identify optimal antigen selections covering a
maximum of patients with ￿10 AR, multiobjective optimization revealed distinct antigen selections by
HPV status. We identified that AR to nonviral antigens differ by HPV status indicating differential
antigen expression. Multiplex serology may be used to characterize antigen expression using serum or
plasma as a tissue‐sparing liquid biopsy. Cancer antigen panels should address the distinct antigen
repertoire of HPV‐positive and HPV‐negative HNSCC.
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antigen selections covering amaximum of patients with ≤10 AR, multiobjective optimization revealed distinct antigen selections by
HPV status. We identiﬁed that AR to nonviral antigens differ by HPV status indicating differential antigen expression.Multiplex
serologymay be used to characterize antigen expression using serum or plasma as a tissue-sparing liquid biopsy. Cancer antigen
panels should address the distinct antigen repertoire of HPV-positive and HPV-negative HNSCC.
What’s new?
Head and neck squamous cell carcinoma remains a deadly disease but new immunotherapeutic approaches are underexplored.
Here the authors tested for antibody responses against human antigens to characterize the expression of such antigens in tumors
positive or negative for human papillomavirus (HPV). Antibody responses were signiﬁcantly different in prevalence and pattern
based on HPV-status in a large patient cohort. The authors urge independent conﬁrmation of their results but point out that
multiplex serology of tumor antigens could be a promising strategy to identify immunotherapeutic targets based on HPV status.
Introduction
Globally, head and neck squamous cell carcinoma (HNSCC)
is diagnosed in almost 900,000 cases annually resulting in
approximately 450,000 cancer deaths per year.1 Human papil-
lomavirus (HPV)-positive oropharyngeal squamous cell carci-
noma has been recognized as a distinct entity of HNSCC
causally associated with HPV.2 Clinically, a signiﬁcant prog-
nostic advantage for HPV-positive oropharyngeal squamous
cell carcinoma has been determined in numerous studies for
different primary treatment strategies.3,4
Cancer antigens are immunogenic proteins or peptides that
can be recognized by the immune system. Shared cancer antigens
include germline antigens such as cancer-testis antigens that are
exclusively expressed in tumor tissue and germline cells5,6 or
cancer-retina antigens,7 oncogenes or mutated tumor-suppressor
genes overexpressed in cancer tissue such as p538 and foreign anti-
gens such as viral antigens.9 The expression of cancer antigens can
be determined by RNA or protein detection in tissue biopsies.
However, such analyses are expensive, availability of tissue may be
limited and an invasive procedure is needed to obtain such biop-
sies. Although antibody responses (AR) to viral antigens have pre-
viously been used to identify HPV-positive patients,10–12 AR to
shared, nonviral antigens may play an important role for immu-
notherapy of HPV-positive andHPV-negativeHNSCC.13,14
The analysis of serum or plasma AR could be a noninva-
sive way to characterize antigen expression indirectly.
The aim of our study was to analyze AR to cancer antigens in
serum or plasma samples of HNSCC patients by HPV status.
Methods
This section was written with respect to the Reporting Recom-
mendations for Tumor Marker Prognostic Studies (REMARK
Guidelines).15
Patients
In our study, 382 patients with histologically diagnosed HNSCC,
an available serum or plasma sample taken prior to the initiation
of treatment and written informed consent according to the
Helsinki Declaration II were selected (with local ethics com-
mittee approval). Patients were treated per institutional guide-
lines at ﬁve large head and neck cancer centers, namely
University Medical Center Ulm, Heidelberg University Hospi-
tal, University Hospital Leipzig (Germany), University Hospi-
tal Padua (Italy) and University Hospital St. Gallen
(Switzerland). Detailed patient characteristics are provided in
Table 1 for oropharyngeal squamous cell carcinoma, cancer of
unknown primary (CUP) and nonoropharyngeal squamous
cell carcinoma.
HPV status
HPV status was determined at the treating center according to
institutional standards. For n = 309 patients, a multiplex
HPV-DNA PCR (GP5+/GP6+ primers followed by Sanger
sequencing for HPV typing as previously described16) and p16
immunohistochemistry (n = 264) was performed. For n = 155
patients, HPV-16 E6*I mRNA status was available. Molecular
HPV status was considered positive if two of the following
three parameters were positive: HPV-DNA of known high-risk
types, HPV-16 E6*I RNA, p16 immunohistochemistry. All
other combinations were considered HPV negative. Molecular
HPV status showed a signiﬁcant correlation with the results
of HPV serology (Pearson correlation coefﬁcient = 0.775,
p < 0.001). Thus, for patients lacking data for determination of
the molecular HPV status, primarily nonoropharyngeal can-
cers, results from HPV serology to high-risk types were used as
a surrogate parameter resulting in a combined marker HPV
(mol/ser).
Material
A serum or plasma sample was prospectively collected prior
to treatment initiation, aliquoted and stored at −20C until
use. Prospective sample collection was in accordance with
local ethics committee approvals.
2 Cancer antibodies in HNSCC differ by HPV status
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Cancer-antigen serology
Among the 382 patients, a serum sample only was available for
260 patients and a plasma sample only for 86 patients. For
36 patients both, serum and plasma samples were available from
the same timepoint. Serum and plasma mean ﬂuorescence inten-
sity (MFI) values showed a high correlation coefﬁcient of r = 0.960
(95%CI 0.95–0.97, p < 0.001, slope 1.097; Supplementary Fig. S1).
The serum sample MFI was taken whenever available and plasma
sampleMFI only if no serum sample was available.
Full-length proteins of selected cancer antigens were pro-
duced for multiplex serology as previously described.17–20 The
cancer antigen panel is shown in Table S1.
Table 1. Patient characteristics by primary site (oropharynx, CUP, nonoropharynx)
Primary site
Total cohortOropharynx (54.9%) CUP (11.8%) Nonoropharynx (44.0%)
n % n % n % n %
T 1 28 13.7 n.a. n.a. 22 16.9 50 13.1
2 89 43.4 n.a. n.a. 32 24.6 121 31.7
3 36 17.6 n.a. n.a. 29 22.3 65 17.0
4 52 25.4 n.a. n.a. 47 36.2 99 25.9
Missing 0 0.0 n.a. n.a. 0 0.0 43 11.3
Total 205 100 47 100 130 100 382 100
N 0 41 20.0 0 0.0 63 48.5 104 27.2
1 26 12.7 17 36.2 20 15.4 63 16.5
2 129 62.9 22 46.8 40 30.8 191 50.0
3 9 4.4 7 14.9 7 5.4 23 6.0
Missing 0 0.0 1 2.1 0 0.0 1 0.3
Total 205 100 47 100 130 100 382 100
M 0 203 99.0 43 91.5 126 96.9 372 97.4
1 2 1.0 4 8.5 4 3.1 10 2.6
Missing 0 0.0 0 0.0 0 0.0 0 0.0
Total 205 100 47 100 130 100 382 100
Stage I 6 2.9 0 0.0 14 10.8 20 5.2
II 17 8.3 0 0.0 17 13.1 34 8.9
III 31 15.1 17 36.2 30 23.1 78 20.4
IVA/B 149 72.7 25 53.2 65 50.0 239 62.6
IVC 2 1.0 4 8.5 4 3.1 10 2.6
Missing 0 0.0 1 2.1 0 0.0 1 0.3
Total 205 100 47 100 130 100 382 100
HPV status (mol or ser) HPV negative 81 39.5 33 70.2 108 83.1 222 58.1
HPV positive 124 60.5 14 29.8 22 16.9 160 41.9
Missing 0 0.0 0 0.0 0 0.0 0 0.0
Total 205 100 47 100 130 100 382 100
Treatment approach Surgical 148 72.2 38 80.9 101 77.7 287 75.1
Nonsurgical 54 26.3 5 10.6 23 17.7 82 21.5
Other (not curative) 2 1.0 2 4.3 4 3.1 8 2.1
Missing 1 0.5 2 4.3 2 1.5 5 1.3
Total 205 100 47 100 130 100 382 100
Sex Male 156 76.1 42 89.4 106 81.5 304 79.6
Female 49 23.9 5 10.6 24 18.5 78 20.4
Total 205 100 47 100 130 100 382 100
Smoking Nonsmoker 51 24.9 9 19.1 32 24.6 92 24.1
Smoker 152 74.1 36 76.6 94 72.3 282 73.8
Missing 2 1.0 2 4.3 4 3.1 8 2.1
Total 205 100 47 100 130 100 382 100
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In brief, genes encoding for 16 cancer-testis antigens, 5
cancer-retina antigens, 8 oncogenes, 29 HPV antigens (from
8 high-risk HPV types) and 2 control antigens (JC virus protein
1 and BK virus protein 1) were cloned into the pGEX4T3 tag
vector for expression in Escherichia coli BL21 as fusion proteins
with N-terminal glutathione-S-transferase and a small C-
terminal tagging epitope (tag) as previously described.19,21 Re-
combinant protein expressed from the parental vector encoding
the glutathione-S-transferase-tag fusion protein without insert
was used to determine serological background. Anti-glutathi-
one-S-transferase (GEHealthcare, Munich, Germany), anti-tag
and anti-mouse HRP secondary antibodies (Dianova) were used
to conﬁrm full-length protein expression and protein integrity.
Multiplex serology was performed as previously descri-
bed.17–19,21 For each antigen and bead set, 2,500 glutathione-
casein coated beads per sample were used and sera or plasma
were measured at 1:1,000 dilutions. Reporter ﬂuorescence of the
beads was determined with the Bio-Plex analyzer (BioRad) and
expressed as MFI of at least 100 beads per set per well. Antigen-
speciﬁc reactivity was calculated as the difference among antigen-
MFI, glutathione-S-transferase-tag-MFI and a blank. This value
was used for further analyses. Cutoffs were determined graphi-
cally for nonviral antigens. For viral antigens, cutoffs were avail-
able from previous studies.12
Statistics
For statistical analysis, the SAMPL guidelines were respected.22
Prism version 7.0c (GraphPad Software, Inc, San Diego,
CA) was used to graph ungrouped AR prevalences.
IBM SPSS statistics version 25.0 was used for statistical
analysis unless indicated otherwise. Two-sided Pearson corre-
lation was used to quantify correlations between MFI values
of AR at baseline.
Frequencies of AR were compared between HPV-positive
and HPV-negative patients using two-sided Chi-squared tests.
For p53, MAGE-A antigens and NY-ESO-1 one-sided testing
was performed based on available data in the literature14,23,24
or own data from independent data sets which were indicating
a signiﬁcantly different prevalence by HPV status. Heatmaps
of correlation coefﬁcients between AR were created using R
(version 3.5.1) and function Diana from R cluster package.
p-Values <0.05 were considered signiﬁcant, but corrections for
multiple testing were performed to reduce statistical errors. Correc-
tions for multiple testing were done using Prism version 7.0c
(GraphPad Software, Inc) with a false discovery rate approach for
each hypothesis using the two-stage step-up method of Benjamini,
Krieger and Yekutieli.25 Given the exploratory nature of the study,
a false discovery rate of up to 15%was tolerated.
The selection of antigens is formulated as a multiobjective
optimization problem. Achieving a maximum coverage within a
cohort of patients with a selection of antigens while at the same
time minimizing the number of antigens in the respective selec-
tion is a mathematical problem that can be solved using multi-
objective optimization methods. Multiobjective optimization was
performed to identify antigen selections with at most ten antigens
covering a maximum of patients in the whole cohort, HPV-
positive or HPV-negative patients.
Instead of a single optimal solution, in multiobjective opti-
mization a set of optimal solutions (Pareto-optimal set) needs
to be found. The solutions of the Pareto-optimal set are the
optimal trade-offs between the optimization objectives.26
We use an adaption of the multiobjective evolutionary algo-
rithm NSGA-II27 to our selection problem. This algorithm is a
population-based metaheuristic where a set of solutions (antigen
selections) is evolved iteratively by applying recombination and
mutation operators to the solutions. After a speciﬁed number of
iterations, the algorithm returns a set of antigen selections con-
taining the trade-offs between the objectives patient coverage and
number of antigens.
From the trade-offs, we select the antigen selection with at
most ten genes that has the largest coverage.
Data availability
Results from multiplex serology are not publicly available, but
may be obtained upon request to the corresponding author.
Results
Patient characteristics of the cohort of 382 patients with HNSCC
are presented in Table 1. The majority of patients had an oropha-
ryngeal tumor, explaining the high rate of HPV-positive patients
(41.6%). Mean age was 61 years in the whole cohort (range:
18–91 years) as well as in HPV-positive (range: 29–85 years) and
HPV-negative patients (range: 18–91 years).
Among the 382 patients, 272 (72%) were seropositive for
any of the 29 autoantigens tested. These results are graphically
presented in Figure 1 with the top ten AR highlighted.
Figure 1. Diagram of antigen reactivities to the panel of
29 autoantigens. Overall 749 antigen reactivities (AR) were found in
272/382 (72%) patients. The top ten antigens (425 reactivities) with
the highest prevalences in the cohort are highlighted. With these
identiﬁed ten antigens, 182/272 (67%) patients with any AR and
182/382 (47.6%) of the whole cohort were covered.
4 Cancer antibodies in HNSCC differ by HPV status
Int. J. Cancer: 00, 00–00 (2019) © 2019 The Authors. International Journal of Cancer published by John Wiley & Sons Ltd on behalf of UICC
T
um
or
Im
m
un
ol
og
y
an
d
M
ic
ro
en
vi
ro
n
m
en
t
AR of individual patients to antigens in the panel and the
overlap between the respective AR for HPV-positive and HPV-
negative were visualized in Figure 2. The overlap between the
respective AR was also different (overlapHPV-negative = 1.09, over-
lapHPV-positive = 0.70). These differences in AR prevalences and
overlap indicate that AR prevalences and patterns between HPV-
positive and HPV-negative patients are distinct.
The rate of patients with 0 to 1 AR was higher in HPV-
positive patients than in HPV-negative patients, but did not
differ by age. A detailed overview of the AR numbers in all
patients by HPV status and by age is provided in Table S2.
Thus, two-sided Chi-squared tests were performed for each of
the 29 autoantigens in the panel comparing AR prevalence in the
group of HPV-positive and HPV-negative patients. For those
antigens for which independent data indicated a different antigen
prevalence, one-sided Chi-sqaured tests were utilized (namely
MAGE-A3, MAGE-A4,MAGE-A9, NY-ESO-1 and p53).
Signiﬁcantly different AR prevalences were found for
MAGE-A3, MAGE-A9 and p53 (Table S3). These results
remained signiﬁcant after correction for multiple testing with a
false discovery rate of 5%. The results expressed as an odds ratio
graph are shown in Figure 3.
We investigated the relationship of the sum of MFI as an indi-
rect measure for antigen load compared to T-category, stage,
HPV status and age. The distribution of the sum of MFI for all
nonviral cancer antigens in the panel was signiﬁcantly different
by T category: The sum of MFI was higher in CUP (4,792) com-
pared to T1/2 (1,408) or T3/T4 (2,554) (Kruskal–Wallis test:
p < 0.001). The mean sum of MFI in Stage I/II (1259) was not
signiﬁcantly lower than in Stage III/IV (2,496) (Whitney–Mann
U-test: p = 0.326). However, the group of Stage I/II patients was
very small (n = 54). In HPV-negative patients (2,609), the mean
sum of MFI was signiﬁcantly higher than in HPV-positive
patients (1,910) (Whitney–Mann U-test: p = 0.009), but did not
differ by age (<65: mean sum of MFI = 1,992; ≥65 = 2,923;
Whitney–MannU-test: p = 0.581).
A correlation analysis of AR MFI values to the tested
autoantigen panel revealed signiﬁcant correlations between
Camel, LAGE-1, NY-ESO-1 and MAGE-A9, the antigens of the
MAGE-A family (MAGE-A1, -A3, -A4, -A9), the SSX-family
(SSX2, SSX4) and between cTAGE5a, OY-TES-1, SpanXa1 and
IMP-1. Interestingly, correlations of AR MFI for HPV-negative
and HPV-positive patients revealed the same signiﬁcant pairwise
correlations, but the values of correlation coefﬁcients were higher
for HPV-positive patients. This becomes evident in the respective
heatmaps resulting in a different hierarchical clustering (Fig. 4).
A much stronger correlation between MAGE-A9, Camel, NY-
ESO-1 and LAGE-1a as well as between cTAGE5a, OY-TES-1,
SpanXa1 and IMP-1 can be seen in the HPV-positive patients.
The respective correlation matrices with detailed values for
correlation coefﬁcients and p-values are provided in Tables S4
(HPV-negative) and S5 (HPV-positive). The correlation matrix
for the whole cohort is presented in a heatmap in Figure S2. The
correlations described above form four visible clusters in the
heatmap. Detailed values for correlation coefﬁcients and p-values
of the whole cohort are provided in Table S6.
Given the different patterns of AR by HPV status, a multi-
objective optimization was performed to identify
HPV-positive HPV-negative
MAGE - A3 13%
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p53 9%
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Figure 2. Individual AR to the cancer antigen panel by HPV status. Antigens are presented in rows, patients in columns. Individuals are
grouped by HPV status. Each AR is symbolized by a bar in the respective antigen row. ARs overlapping with AR to other antigens are
displayed in gray. In the last column, the coverage of the respective antigen within the whole cohort is indicated. The graph shows that
105/159 (66%) of HPV-positive patients and 167/223 (75%) of HPV-negative patients had any AR to the tested autoantigen panel
(Chi-squared, two-sided: p = 0.06).
Gangkofner et al. 5
Int. J. Cancer: 00, 00–00 (2019) © 2019 The Authors. International Journal of Cancer published by John Wiley & Sons Ltd on behalf of UICC
T
um
or
Im
m
un
ol
og
y
an
d
M
ic
ro
en
vi
ro
n
m
en
t
combinations of ≤10 AR resulting in maximum coverage
within the respective group (all patients, HPV-negative, HPV-
positive). These antigen selections were compared to the selec-
tion of the most frequent ten antigens (described in Fig. 1)
with regard to maximum coverage in the respective group and
in all patients (Fig. 5). Selecting the ten most frequent AR
resulted in a coverage of 121/223 (54.3%) in HPV-negative
patients and 61/159 (38.4%) in HPV-positive patients.
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Figure 3. Odds ratio graphs for antibody responses by HPV status. The odds ratio and the 95% conﬁdence interval (95% CI) are shown. The
antibody responses are ordered by prevalence in the whole cohort (n). Signiﬁcant odds ratios are indicated by an asterisk symbol and
printed in black.
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Figure 4. Heatmaps of Pearson correlation coefﬁcients. The heatmap was created using R (version 3.5.1) and function Diana from R cluster
package with a single gradient and two colors for (a) HPV-negative patients and (b) HPV-positive patients.
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After multiobjective optimization for coverage and antigen
number, the coverage in the whole cohort could be increased to
202/382 (52.8%). In HPV-negative patients, 128/223 (57.4%) and
in HPV-positive patients 74/159 (46.5%) could be covered with
this solution. Optimization for HPV-negative patients resulted in
an increased coverage of 135/223 (60.5%) within HPV-negative
patients, but only 56/159 (35.2%) in HPV-positive patients. Opti-
mization for HPV-positive patients resulted in a coverage of
83/159 (52.2%) in the HPV-positive cohort, but only 99/223
(44.3%) in the HPV-negative cohort.
These results show that antigen selections with higher cover-
ages within the respective groups than by selecting the ten most
prevalent AR can be found bymultiobjective optimization.
Discussion
Wewere able to detect AR to a selected panel of 29 cancer antigens
in serum or plasma in the majority of patients from a large
HNSCC cohort. With only 10 out of the 29 antigens, approxi-
mately 66% of all AR could be detected. Signiﬁcantly different
prevalences for AR to MAGE-A3, MAGE-A9 and p53 by HPV
status were found. AR patterns were remarkably different between
HPV-negative and HPV-positive patients. Multiobjective optimi-
zation may be key to develop tailored antigen panels to improve
the performance of multiplex serology to cancer antigens as a liq-
uid biopsy of the cancer-antigen repertoire in the tumor.
MFI values are a quantitative measure and are closely cor-
related with antibody concentrations/antibody titers. They can
be considered as a surrogate for antibody concentrations as
previously shown28,29 and may also be considered an indirect
measure of antigen load.30–32 The mean sum of MFI was
higher in CUP patients and in HPV-negative patients. This
may indicate that the cancer antigen panel selected for our
study was tailored better for HPV-negative patients. To date,
there are limited data available for nonviral cancer antigen
expression in HPV-positive patients. In a recently published
study, AR to 23 cancer antigens were evaluated in 36 HNSCC
patients (27 HPV-negative and 9 HPV-positive HNSCC) and
15 healthy controls.33 Due to the sample size of that study,
the authors were unable to determine conclusive prevalences
of AR by HPV status. Thus, this is the ﬁrst study deﬁning AR
Gene Top 10 All HPV- HPV+ Coverage
10.2%SpanXa1
12.8%MAGE-A3
8.1%NY-ESO-1
8.9%p53
7.1%CT47
8.4%MAGE-A1
6.8%c-myc
7.1%cTAGE5a
7.3%LAGE-1a
9.9%MAGE-A4
6.5%Rhodopsin C
5.5%Recoverin
4.7%HistoneH2B
5.2%Survivin
2.6%SSX-4
5.5%Camel
5.2%Rhodopsin N
6.0%Arrestin
Coverage (all) 47.6% 52.9% 50.0% 47.6%
Coverage (group) 47.6% 52.9% 60.5% 52.2%
Figure 5. Comparison of coverage for ten different cancer antigen selections. Antigens are shown in rows, solutions in columns. The coverage
for the whole cohort and the respective group optimized are provided in the last two rows.
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prevalences to a large panel of cancer antigens in a large
cohort of HNSCC patients.
In two previous studies in melanoma patients,18,20 the preva-
lence of AR to 29 cancer antigens20 and 43 cancer antigens,18
respectively, was higher and AR patterns were also different. In
studies aiming at establishing cancer antigen serology as a diagnos-
tic tool to detect colorectal cancers,17 gastric cancer19 or prostate
cancer34 AR frequencies and patterns were distinct as well. This
indicates disease-speciﬁc patterns of cancer antigen expression.
Even within HNSCC, HPV status deﬁned different patterns of
nonviral cancer antigens. Although the overall prevalence of AR
was not signiﬁcantly different by HPV status, a trend to reduced
frequencies of AR to the selected cancer antigen panel was found
in HPV-positive patients. The fact that 10/29 antigens are sufﬁ-
cient to detect 2/3 of all detected AR further indicates that amodi-
ﬁcation of the cancer antigen panel, preferably semipersonalized
for HPV status may improve coverage within the respective
cohort. A multiobjective optimization for coverage and number
of antigens for all patients and by HPV status resulted in mark-
edly improved coverage in the respective groups with the same
number of antigens (Fig. 5). Thus, a modiﬁcation of the cancer
antigen panel may improve the performance of multiplex serol-
ogy to deﬁne the individual nonviral cancer antigen repertoire.
With regard to the implications of AR to cancer antigens for
cancer-speciﬁc immunity, published data are somewhat conﬂicting.
Several publications indicate a correlation between T cell immunity
and the presence of humoral immunity,35–37 but others did not ﬁnd
an association between antibody and cellular responses.38 Even if
speciﬁc T cells to cancer antigens are found, these seem to be func-
tionally impaired as indicated by increased expression of co-
inhibitory immune checkpoints such as CTLA-4 or LAG-3.30
Immune checkpointmodulation seems to reconstitute functionality
of NY-ESO-1 speciﬁc immunity as previously shown.39
Previously published data indicate that humoral immunity to
cancer antigens may not be a surrogate for active cancer immu-
nity, but rather an indirect measure of antigen expression.30–32,40
Several studies have associated AR to certain cancer antigens with
detrimental or beneﬁcial prognosis.18,20,30 In most studies and for
most antigens, a negative prognostic impact—consistent with our
results—was found. This was also the case for some AR in the
panel described here (data not shown). At the same time, such
patients are candidates for antigen-speciﬁc immunotherapy which
may improve the detrimental outcome. AR serology may identify
patients who are at high risk of death, but also who may beneﬁt
from immunotherapy such as immune checkpoint modulation
potentially in combination with vaccination based on the individ-
ual cancer-antigen repertoire deﬁned bymultiplex serology.
Unfortunately, transcriptome or protein expression data
are not available from the cohort in order to verify protein
expression in AR positive patients which represents a limita-
tion to our study.
In the future, a modiﬁcation of the antigen panel for multi-
plex serology may improve coverage of patients to identify
patients who may beneﬁt from immunotherapy. The results of
this analysis are exploratory and need validation in indepen-
dent cohorts, preferably from prospective clinical trials.
In conclusion, our data show that AR patterns to nonviral
antigens are distinct based upon HPV status which can be uti-
lized for the development of immunotherapy for HNSCC.
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